BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.26 Billion USD | 13.63% |
| 2022 | 1.99 Billion USD | -16.94% |
| 2021 | 2.4 Billion USD | 38.78% |
| 2020 | 1.73 Billion USD | 173.14% |
| 2019 | 633.93 Million USD | 27.8% |
| 2018 | 496.03 Million USD | 36.93% |
| 2017 | 362.24 Million USD | -10.74% |
| 2016 | 405.81 Million USD | 247.55% |
| 2015 | 116.76 Million USD | 319.22% |
| 2014 | 27.85 Million USD | -44.87% |
| 2013 | 50.52 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.34 Billion USD | 1.67% |
| 2024 Q1 | 2.3 Billion USD | 1.74% |
| 2023 Q4 | 2.26 Billion USD | 28.74% |
| 2023 Q1 | 1.79 Billion USD | -9.84% |
| 2023 Q3 | 1.76 Billion USD | -8.73% |
| 2023 FY | 2.26 Billion USD | 13.63% |
| 2023 Q2 | 1.93 Billion USD | 7.26% |
| 2022 Q4 | 1.99 Billion USD | -3.62% |
| 2022 Q3 | 2.07 Billion USD | -0.23% |
| 2022 FY | 1.99 Billion USD | -16.94% |
| 2022 Q2 | 2.07 Billion USD | -2.82% |
| 2022 Q1 | 2.13 Billion USD | -11.11% |
| 2021 Q3 | 1.92 Billion USD | 0.62% |
| 2021 Q1 | 1.81 Billion USD | 4.96% |
| 2021 Q4 | 2.4 Billion USD | 24.55% |
| 2021 Q2 | 1.91 Billion USD | 5.5% |
| 2021 FY | 2.4 Billion USD | 38.78% |
| 2020 Q1 | 1.24 Billion USD | 95.63% |
| 2020 Q2 | 1.35 Billion USD | 9.41% |
| 2020 Q4 | 1.73 Billion USD | 36.35% |
| 2020 FY | 1.73 Billion USD | 173.14% |
| 2020 Q3 | 1.26 Billion USD | -6.41% |
| 2019 Q4 | 633.93 Million USD | 8.03% |
| 2019 FY | 633.93 Million USD | 27.8% |
| 2019 Q2 | 579.05 Million USD | 5.37% |
| 2019 Q3 | 586.83 Million USD | 1.34% |
| 2019 Q1 | 549.55 Million USD | 10.79% |
| 2018 Q2 | 427.18 Million USD | 21.98% |
| 2018 FY | 496.03 Million USD | 36.93% |
| 2018 Q3 | 425.19 Million USD | -0.47% |
| 2018 Q4 | 496.03 Million USD | 16.66% |
| 2018 Q1 | 350.2 Million USD | -3.32% |
| 2017 FY | 362.24 Million USD | -10.74% |
| 2017 Q4 | 362.24 Million USD | 27.3% |
| 2017 Q3 | 284.57 Million USD | 39.63% |
| 2017 Q1 | 68.31 Million USD | -83.17% |
| 2017 Q2 | 203.8 Million USD | 198.34% |
| 2016 Q2 | 31.18 Million USD | 40.91% |
| 2016 Q4 | 405.81 Million USD | 752.67% |
| 2016 Q3 | 47.59 Million USD | 52.62% |
| 2016 Q1 | 22.12 Million USD | -81.05% |
| 2016 FY | 405.81 Million USD | 247.55% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q3 | 35.53 Million USD | 31.34% |
| 2015 Q4 | 116.76 Million USD | 228.63% |
| 2015 FY | 116.76 Million USD | 319.22% |
| 2015 Q2 | 27.05 Million USD | 0.0% |
| 2014 Q4 | 27.85 Million USD | 0.0% |
| 2014 FY | 27.85 Million USD | -44.87% |
| 2013 FY | 50.52 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -1384.084% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 67.868% |